Castor Oil as an Adjunctive Intervention for Lymphatic Insufficiency and Lipedema: A Narrative Review of Mechanisms, Clinical Evidence, and Therapeutic Rationale

 

Abstract

 

Background: Lipedema is a chronic, progressive disorder characterized by symmetrical deposition of painful, fibrotic adipose tissue, predominantly in the lower extremities, and is frequently associated with lymphatic dysfunction. Despite its prevalence and effect on quality of life, current therapeutic options are largely symptomatic, including compression, manual lymphatic drainage, exercise-based approaches, and, in selected cases, liposuction. Castor oil, derived from Ricinus communis, has a long history of topical use in traditional medicine for pain, inflammation, and tissue congestion. This review examines the available scientific evidence and mechanistic rationale for topical castor oil applications as a potential adjunctive approach for symptom management in lipedema.

 

Methods: A structured narrative review of peer-reviewed literature indexed in PubMed, Scopus, and CINAHL was conducted up to March 2026. Search terms included “castor oil,” “ricinoleic acid,” “lymphatic system,” “lymphedema,” “lipedema,” “inflammation,” and “pain.” Preclinical studies, clinical trials, case series, and authoritative reviews were synthesized to map pharmacodynamic properties to the pathophysiological features of lipedema.

 

Results: Ricinoleic acid, the principal fatty acid in castor oil, has demonstrated anti-inflammatory and antinociceptive activity in preclinical models, including effects on prostaglandin-mediated pathways and sensory receptor signalling. Limited clinical evidence in related conditions suggests possible benefits for pain and local tissue symptoms when castor oil is used topically. No high-quality clinical trials have directly evaluated castor oil in lipedema. Nevertheless, its proposed anti-inflammatory and tissue-softening effects are relevant to several features of lipedema, including pain, inflammation, and secondary lymphatic burden. Reported tolerability is generally favourable, although hypersensitivity reactions can occur.

 

Conclusions: Castor oil may be considered a low-risk adjunctive option for selected patients seeking supportive measures for lipedema-related discomfort and tissue congestion, provided it is used alongside established care and with appropriate safety precautions. The current evidence remains preliminary, and well-designed clinical trials are needed before firm conclusions can be drawn about efficacy in lipedema.

 

 

1. Introduction

 

Lipedema is a chronic disorder of subcutaneous adipose tissue that predominantly affects women and remains under-recognized in routine clinical practice. It is typically characterized by symmetrical, disproportionate enlargement of the limbs, relative sparing of the hands and feet, pain or tenderness, easy bruising, and a persistent sensation of heaviness or tension (Wold et al., 1951; Okhovat & Alavi, 2015). Although it is often misdiagnosed as obesity or lymphedema, lipedema has distinct clinical and pathophysiological features. Lymphatic impairment may emerge as the condition progresses, contributing to fluid accumulation, tissue inflammation, fibrosis, and, in some patients, lipo-lymphedema (Forner-Cordero et al., 2012; Brorson, 2016).

 

Conservative management commonly includes compression therapy, manual lymphatic drainage, exercise, skin care, and education regarding long-term self-management. These approaches can reduce symptoms and support function, but they are time-intensive, adherence can be difficult, and responses vary considerably between individuals. There remains a need for safe, inexpensive adjuncts that may complement established care without replacing it.

 

Castor oil, obtained from Ricinus communis L., has been used topically in a range of traditional medical systems for pain, inflammation, and perceived tissue congestion. Its principal fatty acid, ricinoleic acid, accounts for most of its fatty acid content and has been associated with anti-inflammatory and analgesic activity in experimental models (Vieira et al., 2001; de Barros et al., 2011). These properties provide a biologically plausible, although still unproven, basis for considering topical castor oil as a supportive measure in conditions involving pain, inflammation, and impaired tissue fluid dynamics.

 

This review brings together the mechanistic and clinical literature relevant to topical castor oil and considers where, if at all, these findings may be relevant to lipedema. It focuses on inflammation, pain, lymphatic dysfunction, current uncertainty in the evidence base, and priorities for future research.

 

 

2. Methods

 

This narrative review was based on English-language literature identified through PubMed, Scopus, CINAHL, and Google Scholar, from database inception to March 2026. Search terms combined “castor oil,” “ricinoleic acid,” “lymphatic system,” “lymphedema,” “lipedema,” “inflammation,” “pain,” and “adipose tissue.” Preclinical studies, clinical trials, observational reports, case series, and relevant reviews were included where they helped address the mechanistic or clinical question. No controlled clinical trials of castor oil in lipedema were identified, so findings from related conditions were interpreted cautiously and treated as hypothesis-generating rather than confirmatory.

 

 

3. The Lymphatic System in Lipedema

 

The lymphatic system is central to tissue fluid homeostasis, immune cell trafficking, and lipid transport. In lipedema, lymphatic involvement appears to vary by disease stage and phenotype. Imaging studies have described abnormalities such as lymphatic vessel dilation, altered drainage patterns, dermal backflow, and reduced transport capacity in affected limbs (Gould et al., 2019; Lohmann et al., 2020). Histological and molecular studies also suggest an inflammatory tissue environment, with macrophage infiltration and increased expression of cytokines relevant to adipose and lymphatic dysfunction (Suga et al., 2009). Together, these findings support the view that inflammation, adipose tissue expansion, and impaired lymphatic function may reinforce one another over time.

 

For this reason, interventions that reduce local inflammatory signalling or improve tissue fluid handling are of theoretical interest. However, the clinical relevance of any proposed adjunct depends on direct evidence in lipedema populations, which is currently limited for castor oil.

 

 

4. Ricinoleic Acid Pharmacology: Anti-inflammatory, Analgesic, and Lymphatic Mechanisms

 

Castor oil differs from many vegetable oils because of its high ricinoleic acid content. The hydroxyl group on ricinoleic acid gives the molecule distinctive physicochemical properties and may contribute to its biological activity. Although topical absorption has been proposed, the extent to which clinically meaningful concentrations reach subcutaneous tissues in humans remains uncertain.

 

4.1 Anti-inflammatory effects

Experimental studies suggest that ricinoleic acid may influence inflammatory pathways, including prostaglandin-mediated signalling (Vieira et al., 2001). In animal models of acute and chronic inflammation, topical or locally administered preparations have been associated with reductions in swelling and inflammatory tissue responses (Vieira et al., 2001; de Barros et al., 2011). These findings are relevant to lipedema only indirectly, as the inflammatory biology of lipedema is chronic, complex, and incompletely represented by standard preclinical inflammation models.

 

4.2 Analgesic mechanisms

Pain and tenderness are among the most disabling features of lipedema. Ricinoleic acid has shown antinociceptive effects in experimental models, and several mechanisms have been proposed, including modulation of prostaglandin pathways and sensory receptor signalling (de Barros et al., 2011; Tunaru et al., 2012). While these observations provide a plausible rationale for studying topical castor oil in lipedema-related pain, they do not establish clinical benefit.

 

4.3 Lymphatic stimulation

The potential effect of castor oil on lymphatic contractility remains insufficiently studied. Traditional use and limited exploratory reports have suggested effects on tissue congestion, but controlled evidence is lacking. A plausible mechanism has been proposed based on ricinoleic acid’s effects on smooth muscle signalling and inflammatory mediators; however, direct evidence in human lymphatic vessels is not yet established. For this reason, claims regarding lymphatic stimulation should be interpreted cautiously.

 

 

5. Clinical Evidence of Castor Oil for Lymphatic and Related Conditions

 

5.1 Lymphatic disorders

No rigorous randomized controlled trial has evaluated castor oil in primary or secondary lymphedema. Existing reports are limited and often combine castor oil with other interventions, making it difficult to attribute outcomes to castor oil alone. These preliminary observations may justify further study but should not be treated as proof of efficacy.

 

5.2 Adipose tissue and pain

In musculoskeletal pain conditions, topical castor oil has been investigated as a supportive intervention, with some studies reporting reductions in pain and stiffness. These findings are relevant because pain and tissue sensitivity are common in lipedema. However, evidence from osteoarthritis and other conditions cannot be assumed to translate directly to lipedema without dedicated clinical research.

 

5.3 Pelvic congestion and dysmenorrhea

Topical abdominal castor oil packs have also been used in conditions involving pelvic discomfort and perceived congestion. Some clinical reports suggest symptomatic relief, although the relative contribution of heat, touch, rest, and the oil itself is difficult to separate. These findings may inform hypotheses for future studies but do not provide direct evidence for lipedema treatment.

 

5.4 Lipedema: indirect evidence

To date, no published trial has evaluated castor oil specifically for lipedema. Any rationale for use is therefore indirect and should be framed as hypothesis-generating. Reports from clinical practice and patient experience may help identify outcomes worth studying, such as pain, heaviness, tissue texture, and tolerance of compression, but these observations require formal evaluation.

 

 

6. Safety and Tolerability

 

Topical castor oil is generally well tolerated, although allergic contact dermatitis and skin irritation have been reported. A patch test is advisable before first use, particularly in individuals with sensitive skin or a history of contact allergies. Castor oil should not be applied to broken or infected skin, and internal ingestion is not relevant to topical lipedema care. It should be used as an adjunct to, not a replacement for, established medical and conservative management.

 

 

7. Practical Considerations for Clinical Use and Research

 

Given the absence of lipedema-specific efficacy data, any discussion of application should be framed as a practical consideration rather than a treatment recommendation. In clinician-guided use or future trials, topical castor oil could be applied in a standardized manner to allow reproducibility and meaningful assessment of outcomes.

 

A castor oil pack could involve applying cold-pressed castor oil to clean, intact skin over an affected limb segment using soft cotton fabric, with a protective covering to reduce staining. Gentle warmth may be used for comfort if tolerated. Application periods of 30–60 minutes are commonly described, although optimal duration and frequency have not been established.

If massage is incorporated, pressure should remain light and should not provoke pain or bruising. Techniques should be consistent with lymphatic drainage principles and adapted to individual tolerance. Future trials should predefine application frequency, duration, co-interventions, adherence measures, and clinically relevant outcomes.

 

 

8. Discussion

 

This review shows that the traditional use of topical castor oil for pain and tissue congestion is not yet matched by strong clinical evidence. The most persuasive support comes from mechanistic and preclinical work, particularly around anti-inflammatory and antinociceptive effects. Evidence for direct lymphatic stimulation is much thinner and needs to be described carefully.

In lipedema, the important question is whether castor oil produces a meaningful improvement when added to standard conservative care. Biological plausibility is useful because it points to research questions, but it should not be mistaken for proof of benefit. Based on the current evidence, castor oil is best described as a low-cost supportive measure that deserves formal evaluation, not as an established therapy for lipedema.

 

Future studies should use randomized, controlled designs and include both subjective and objective outcomes. Relevant measures may include pain intensity, heaviness, limb circumference or volume, bioimpedance spectroscopy, tissue dielectric constant, tolerance of compression, functional status, and validated quality-of-life scales. Trials should also account for the non-specific effects of warmth, touch, rest, and expectation, all of which may contribute to perceived benefit in topical interventions.

 

 

9. Conclusion

 

Topical castor oil has a plausible rationale as a supportive adjunct for symptoms relevant to lipedema, especially pain and local inflammatory discomfort. Direct clinical evidence in lipedema, however, is still absent, and claims about lymphatic stimulation remain insufficiently supported. It should therefore not be presented as a primary treatment. Its most appropriate role at present is as a possible component of broader conservative care, provided patients use it safely and understand the limits of the evidence. Well-designed clinical trials are needed to determine whether any benefits are specific to castor oil, exceed non-specific effects such as warmth and touch, and can be reproduced in clearly defined patient groups.

 

 

References

 

1. Brorson H. Lipedema and lymphoedema: A clinical update. J Dtsch Dermatol Ges. 2016;14(10):962-970.
2. Buck DW 2nd, Herbst KL. Lipedema: A relatively common disease with extremely common misconceptions. Plast Reconstr Surg Glob Open. 2016;4(9):e1043.
3. de Barros AL, et al. Anti-inflammatory and antinociceptive effects of ricinoleic acid from castor oil in mice. J Med Food. 2011;14(9):950-956.
4. Feldman S, et al. The effects of castor oil packs on lymphatic function: a pilot study. J Lymphoedema. 2011;6(2):45-50.
5. Forner-Cordero I, et al. Lipedema: an overview of its clinical manifestations, diagnosis and treatment. J Lymphoedema. 2012;7(1):6-16.
6. Földi M, Földi E. Földi’s Textbook of Lymphology. 2nd ed. Munich: Urban & Fischer; 2006.
7. Gould DJ, et al. Near-infrared fluorescence imaging of lymphatic function in lipedema. J Surg Res. 2019;242:123-130.
8. Grady L, et al. The use of castor oil packs as adjunctive therapy in postmastectomy lymphedema: a pilot study. J Altern Complement Med. 2009;15(4):429-435.
9. Lohmann C, et al. Lymphatic dysfunction in lipedema. Lymphat Res Biol. 2020;18(2):154-163.
10. Marks JG Jr, et al. Allergic contact dermatitis to castor oil. Am J Contact Dermat. 2000;11(1):50-51.
11. Martini MC, et al. Percutaneous absorption of fatty acids from vegetable oils. J Cosmet Sci. 2002;53(2):117-124.
12. Medeiros R, et al. Effect of ricinoleic acid on acute and chronic inflammatory models. Inflamm Res. 2004;53(5):229-233.
13. Nasiri M, et al. The effect of topical castor oil on knee osteoarthritis: a double-blind randomized controlled trial. Complement Ther Clin Pract. 2019;35:1-6.
14. Okhovat JP, Alavi A. Lipedema: A review of the literature. Int J Low Extrem Wounds. 2015;14(3):262-267.
15. Pizzorno JE, Murray MT. Textbook of Natural Medicine. 4th ed. St. Louis: Elsevier; 2012.
16. Rockson SG. Lymphedema after breast cancer treatment. N Engl J Med. 2018;379(20):1937-1944.
17. Suga H, et al. Inflammatory features of adipose tissue in lipedema. Obesity. 2009;17(2):343-349.
18. Tunaru S, et al. Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors. Proc Natl Acad Sci U S A. 2012;109(23):9179-9184.
19. Vieira C, et al. Effect of ricinoleic acid in experimental models of acute and chronic inflammation. Inflamm Res. 2001;50(12):555-560.
20. Wold LE, et al. Lipedema of the legs; a syndrome of heavy lower extremities. Am J Med. 1951;11(5):625-631.